Comparative Pharmacology
Head-to-head clinical analysis: AMITRIPTYLINE HYDROCHLORIDE versus AVENTYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMITRIPTYLINE HYDROCHLORIDE versus AVENTYL.
AMITRIPTYLINE HYDROCHLORIDE vs AVENTYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits reuptake of serotonin and norepinephrine, leading to increased concentrations at synaptic cleft; also blocks histamine H1, alpha-1 adrenergic, and muscarinic cholinergic receptors.
Nortriptyline, the active ingredient, inhibits the reuptake of norepinephrine and serotonin in the central nervous system, potentiating their effects. It also has anticholinergic and antihistaminergic properties.
Oral: 25-150 mg daily in divided doses or as a single bedtime dose; maximum 300 mg/day.
Adults: 25 mg orally 3 to 4 times daily, maximum 150 mg/day.
None Documented
None Documented
Terminal elimination half-life is 15-35 hours (range 9-46 hours); clinical context: steady-state concentrations achieved within 7-10 days; may be prolonged in elderly, hepatic impairment, or CYP2D6 poor metabolizers.
Terminal elimination half-life: 19-24 hours; requires 4-6 days to reach steady state.
Primarily renal (approximately 30-50% as unchanged drug and metabolites, mainly glucuronide conjugates and hydroxylated metabolites). Fecal excretion accounts for <5%. Enterohepatic recirculation may occur.
Renal (30% as unchanged drug and metabolites); biliary/fecal (70% as metabolites)
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant